|
|
Article: Celiac Disease - Licensing Opportunities Exist in Untapped Market as Report Estimates That under Optimal Conditions Drug Sales Could Reach $8 Billion by 2019.
- Article from:
- Biotech Week
- Article date:
- May 20, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Research and Markets(http://www.researchandmarkets.com/research/8b2ed8/celiac_disease_l) has announced the addition of the "Celiac Disease - Licensing Opportunities Exist in Untapped Market" report to their offering (see also Research and Markets).
Low disease awareness, poor diagnosis rates, combined with a lack of pharmaceutical industry involvement, has kept celiac disease from the limelight. However, this is changing as evidenced by Shires recent involvement in the pipeline. Datamonitor believes a drug for celiac disease is up to 5 years away and this untapped gastrointestinal indication has the potential to become a lucrative market.
Scope
...